Teleflex Inc. is making another big investment in a novel product that it believes can boost the revenue growth of its broad product portfolio with the $1.1bn acquisition of privately held NeoTract Inc., manufacturer of the UroLift system for minimally invasive treatment of benign prostate hyperplasia, the companies announced Sept. 5.
Teleflex Adds Minimally Invasive BPH System With NeoTract Buy
Teleflex is forking out over $1bn for privately held NeoTract. The latter has seen its revenues grow rapidly due to market enthusiasm for its UroLift system for treating lower urinary tract symptoms related to benign prostatic hyperplasia.